Analystreport

Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report